Home » Market News » DirectorsTalk Highlights » Avacta eyes diagnostic applications for alternative to antibody-based reagents
Avacta Group Plc

Avacta eyes diagnostic applications for alternative to antibody-based reagents

While diagnostic test makers have come to rely on antibodies for test development – a whole class of tests, immunodiagnostics, are based on antibodies – issues around them have been known for decades with industry and researchers working to solve them.

Against that backdrop, one firm, Avacta, has developed an alternative to antibodies with a technology called Affimers, and according to company officials, a growing number of diagnostic companies are exploring the use of the reagents.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.